About this trial
Prolonged pregnancy could lead to perinatal and maternal complications. Oxytocin has been wildly used for induction of labour, but prolonged labour continued to occur with its attendant sequelae. Propranolol, a non-selective B-adrenergic inhibitor has been found to facilitate labour progress in some studies, by the blockade of the effects of catecholamines on the uterus though there are conflicting reports, with the only meta-analysis inconclusive due to few studies used; hence, the need to further study its role in induction of labour. The aim of this study is to assess the role of oral Propranolol in decreasing the induction-delivery with oxytocin
Eligibility criteria
This trial accepts healthy volunteersQualifiers
singleton foetus
cephalic presentation at term
Disqualifiers
Patients on beta blockers
Contraindications to labour or vaginal delivery
Multiple gestations
Preterm labour
Trial design
Parallel
Treatments tested in this trial
Propranolol
DrugA set of 154 numbers will receive oxytocin and propranolol once or twice 6 hours apart. the first dose will be from 10 minutes before commencement of oxytocin titration and the second dose will be 6 hours from the first dose if delivery has not taken place.
Placebo
Other interventionA set of 154 numbers will receive oxytocin and placebo once or twice 6 hours apart. the first dose will be from 10 minutes before commencement of oxytocin titration and the second dose will be 6 hours from the first dose if delivery has not taken place.
Treatment groups
Trial outcomes
Primary outcomes
Mean duration of first, second and third stage of labour
this is to assess the mean duration of the first, second and third stages of labour
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: